A narrative review examines new therapies for vitiligo, indicating potential for improved repigmentation and stabilization.
The approval of topical ruxolitinib marks a pivotal step toward precision therapy in vitiligo. Ongoing studies of combination and maintenance regimens offer promise for sustained repigmentation and disease stabilization. However, optimizing long-term outcomes requires continued translational research to elucidate mechanisms of relapse, improve accessibility of emerging therapies and personalize treatment strategies to individual disease phenotypes.
No takes yet. Share an insight, caveat, or question.
Mendonça et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: